Cabozantanib is an anticancer chemotherapeutic compound that has been approved to treat medullary thyroid cancer and is in clinical trials as a treatment for other types of solid tumors. Cabozantanib exerts its anticancer activity through inhibition of Met, RET, and VEGFR2, increasing apoptosis and inhibiting cell growth and osteoclast proliferation in vitro and in vivo.
Grades: ≥98%